Login to Your Account

Clinic Roundup

Thursday, August 22, 2013
Catabasis Pharmaceuticals Inc., of Cambridge, Mass., started Pathways I, a Phase II trial investigating the safety, tolerability and efficacy of CAT-2003, an oral SMART Linker conjugate constructed using the company's technology.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription